JP7362725B2 - アネトールトリチオンおよびその誘導体のシクロデキストリン複合体を含む医薬組成物 - Google Patents

アネトールトリチオンおよびその誘導体のシクロデキストリン複合体を含む医薬組成物 Download PDF

Info

Publication number
JP7362725B2
JP7362725B2 JP2021512682A JP2021512682A JP7362725B2 JP 7362725 B2 JP7362725 B2 JP 7362725B2 JP 2021512682 A JP2021512682 A JP 2021512682A JP 2021512682 A JP2021512682 A JP 2021512682A JP 7362725 B2 JP7362725 B2 JP 7362725B2
Authority
JP
Japan
Prior art keywords
cyclodextrin
day
formula
dithiol
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021512682A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021536472A (ja
JP2021536472A5 (https=
JPWO2020049166A5 (https=
Inventor
ピノー，ニコラス
ムスタファ ベルグサー，エル
ターピン，フレデリック
フォーニアル，アン－ガエル
ドゥレイメーカー，アスウィン
オドール，ナターシャ
コック，イーネ デ
Original Assignee
オーピーツー ドラッグス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オーピーツー ドラッグス filed Critical オーピーツー ドラッグス
Publication of JP2021536472A publication Critical patent/JP2021536472A/ja
Publication of JP2021536472A5 publication Critical patent/JP2021536472A5/ja
Publication of JPWO2020049166A5 publication Critical patent/JPWO2020049166A5/ja
Application granted granted Critical
Publication of JP7362725B2 publication Critical patent/JP7362725B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021512682A 2018-09-06 2019-09-06 アネトールトリチオンおよびその誘導体のシクロデキストリン複合体を含む医薬組成物 Active JP7362725B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862727691P 2018-09-06 2018-09-06
EP18306172 2018-09-06
EP18306172.0 2018-09-06
US62/727,691 2018-09-06
PCT/EP2019/073873 WO2020049166A1 (en) 2018-09-06 2019-09-06 Pharmaceutical composition comprising cyclodextrin compexes of anethole trithione or derivatives thereof

Publications (4)

Publication Number Publication Date
JP2021536472A JP2021536472A (ja) 2021-12-27
JP2021536472A5 JP2021536472A5 (https=) 2022-09-15
JPWO2020049166A5 JPWO2020049166A5 (https=) 2022-09-15
JP7362725B2 true JP7362725B2 (ja) 2023-10-17

Family

ID=67841092

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021512682A Active JP7362725B2 (ja) 2018-09-06 2019-09-06 アネトールトリチオンおよびその誘導体のシクロデキストリン複合体を含む医薬組成物

Country Status (11)

Country Link
US (1) US12295969B2 (https=)
EP (1) EP3846856A1 (https=)
JP (1) JP7362725B2 (https=)
KR (1) KR20210054540A (https=)
CN (1) CN113038969A (https=)
AU (2) AU2019336943A1 (https=)
BR (1) BR112021003997A2 (https=)
CA (1) CA3111886A1 (https=)
IL (1) IL281161B2 (https=)
MX (1) MX2021002611A (https=)
WO (1) WO2020049166A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022123038A1 (en) * 2020-12-10 2022-06-16 OP2 Drugs Anethole trithione administration regimen for the prevention or treatment of ischemia-reperfusion injuries
EP4112051A1 (en) * 2021-06-30 2023-01-04 Op2 Drugs Anethole trithione for the treatment of vasculitides
CN114558004B (zh) * 2022-03-29 2023-08-11 奎马特里克斯有限公司 Qtx125药物制剂
CN115738757B (zh) * 2022-11-24 2024-03-29 中国海洋大学 一种基于磺丁基-β-环糊精离子传输通道的单价阳离子选择性分离膜及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262165A (en) 1992-02-04 1993-11-16 Schering Corporation Transdermal nitroglycerin patch with penetration enhancers
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
CA2222133C (en) 1995-06-07 2002-12-24 Cygnus, Inc. Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
AU5474198A (en) * 1996-12-24 1998-07-17 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
CN1771938A (zh) 2004-11-09 2006-05-17 胡才忠 茴三硫脂质体及其制备方法
JP6876047B2 (ja) * 2015-09-08 2021-05-26 オーピーツー ドラッグス ミトコンドリアの活性酸素種（ｒｏｓ）産生に関連する疾患の治療のための化合物
BR112018004518A2 (pt) * 2015-09-08 2019-03-19 OP2 Drugs compostos para o tratamento de doenças ligadas à produção de espécies reativas de oxigênio (ros) mitocondriais
AU2018232799B2 (en) * 2017-03-07 2021-11-25 Centre Hospitalier Universitaire De Bordeaux Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DOLLO, Gilles et al.，Journal of Pharmaceutical Sciences，1999年，Vol.88, No.9，p.889-895
LEFEUVRE, Claudia et al.，Journal of Pharmaceutical Sciences，1999年，Vol.88, No.10，p.1016-1020
ZHENG, Ying et al.，Journal of Pharmaceutical Sciences，2005年，Vol.94, No.5，p.1079-1089

Also Published As

Publication number Publication date
AU2019336943A1 (en) 2021-03-18
JP2021536472A (ja) 2021-12-27
IL281161B2 (en) 2024-01-01
KR20210054540A (ko) 2021-05-13
IL281161B1 (en) 2023-09-01
US20210308173A1 (en) 2021-10-07
BR112021003997A2 (pt) 2021-05-25
MX2021002611A (es) 2021-07-21
CA3111886A1 (en) 2020-03-12
IL281161A (en) 2021-04-29
CN113038969A (zh) 2021-06-25
AU2025204144A1 (en) 2025-06-26
EP3846856A1 (en) 2021-07-14
US12295969B2 (en) 2025-05-13
WO2020049166A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
JP7362725B2 (ja) アネトールトリチオンおよびその誘導体のシクロデキストリン複合体を含む医薬組成物
US20230042785A1 (en) Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
JPWO2016039433A1 (ja) 新規なヒドロキサム酸誘導体またはその塩を含有する医薬組成物
JP2008520576A (ja) 眼性血管新生症および黄斑変性の処置に有用な組成物
US20070134341A1 (en) Compositions of lipoxygenase inhibitors
JP2020511450A (ja) ミトコンドリアの活性酸素種（ｒｏｓ）産生に関連する疾患の治療のためのデスメチルアネトールトリチオン誘導体
US20110245207A1 (en) Method for moderately increasing the proton conductivity of biological membranes with the aid of mitochondria-targeted delocalized cations
JP5677856B2 (ja) 医薬組成物
US20210346332A1 (en) Compositions and methods for treating and preventing leber's hereditary optic neuropathy
TW202432120A (zh) 注射用組合物、包含其之醫藥調配物以及製備該組合物之方法
US20130203843A1 (en) Mild cationic mitochondrial uncouplers
US20120245223A1 (en) Use of gymnodimine, analogues and derivatives for the treatment and/or prevention of neurodegenerative diseases associated with tau and b-amyloid
EP3045169A1 (en) Aqueous solution formulation, and manufacturing method for same
CN101642435A (zh) 异甜菊醇及其衍生物脂质体制剂及其制备方法
HK40111340A (zh) 可注射组合物、包含其的药物制剂以及制备该组合物的方法
HK40101801A (zh) 基於β取代的β-氨基酸衍生物的化学治疗剂的药物组合物
Vukićević Formulation of photoreactive drug substances: The role of excipients and type of preparation
TW201841640A (zh) 週期素依賴型激酶7(cdk7)抑制劑之組合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220906

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220906

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230905

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231004

R150 Certificate of patent or registration of utility model

Ref document number: 7362725

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150